Is pain in patients with haematological malignancies under-recognised? The results from Italian ECAD-O survey

Bandieri, Elena; Sichetti, Daniela; Luppi, Mario; Biagio, Katiuscia Di; Ripamonti, Carla; Tognoni, Gianni; Belfiglio, Maurizio; Romero, Marilena

doi:10.1016/j.leukres.2010.08.013

Cited by 17 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with hematologic malignancies have significant palliative care needs, including high symptom burden, 15-17 yet remain less likely than patients with solid tumors to receive specialist palliative care services and more likely to receive aggressive health care at the end of life. 18 Specifically, patients with blood cancers are less frequent users of hospice services, 19 less likely to be seen by consultative palliative care services in the hospital, 20 more likely to die in a hospital or intensive care unit, 21-23 and more likely to receive chemotherapy in the last few weeks of life.…”

Section: Introductionmentioning

confidence: 99%

Perceptions of Palliative Care Among Hematologic Malignancy Specialists: A Mixed-Methods Study

LeBlanc

O’Donnell

Crowley‐Matoka

et al. 2015

JOP

156

125

View full text Add to dashboard Cite

Background Patients with hematologic malignancies are less likely to receive specialist palliative care services than patients with solid tumors. Reasons for this difference are poorly understood. Methods This was a multisite, mixed-methods study to understand and contrast perceptions of palliative care among hematologic and solid tumor oncologists, using surveys assessing referral practices, and in-depth semi-structured interviews exploring views of palliative care. We compared referral patterns using standard statistical methods. We analyzed qualitative interview data using constant comparative methods, to explore reasons for observed differences. Results Among 66 interviewees, 23 oncologists cared exclusively for patients with hematologic malignancies; 43 treated only patients with solid tumors. Seven of 23 hematologic oncologists (30%) reported never referring to palliative care; all solid tumor oncologists had previously referred. In qualitative analyses, most hematologic oncologists viewed palliative care as end-of-life care, while most solid tumor oncologists viewed palliative care as a subspecialty that could assist with complex cases. Solid tumor oncologists emphasized practical barriers to palliative care referral, such as appointment availability and reimbursement issues. Hematologic oncologists emphasized philosophical concerns about palliative care referrals, including different treatment goals, responsiveness to chemotherapy, and a preference to control even palliative aspects of patient care. Conclusions Most hematologic oncologists view palliative care as end-of-life care, while solid tumor oncologists more often view palliative care as a subspecialty for co-managing complex patients. Efforts to integrate palliative care into hematologic malignancy practices will require solutions that address unique barriers to palliative care referral experienced by hematologic malignancy specialists.

show abstract

Section: Introductionmentioning

confidence: 99%

Perceptions of Palliative Care Among Hematologic Malignancy Specialists: A Mixed-Methods Study

LeBlanc

O’Donnell

Crowley‐Matoka

et al. 2015

JOP

156

125

View full text Add to dashboard Cite

show abstract

“…Patients with hematologic malignancies have significant palliative care needs, including high symptom burden [15][16][17] ; however, they remain less likely than patients with solid tumors to receive specialist palliative care services and more likely to receive aggressive health care at the end of life. 18 Specifically, patients with blood cancers are less frequent users of hospice services, 19 less likely to be seen by consultative palliative care services in the hospital, 20 more likely to die in a hospital or intensive care unit, [21][22][23] and more likely to receive chemotherapy in the last few weeks of life.…”

mentioning

confidence: 99%

Perceptions of palliative care among hematologic malignancy specialists: A mixed-methods study.

LeBlanc

O’Donnell

Crowley-Makota

et al. 2014

JCO

View full text Add to dashboard Cite

Purpose: Patients with hematologic malignancies are less likely to receive specialist palliative care services than patients with solid tumors. Reasons for this difference are poorly understood. Methods:This was a multisite, mixed-methods study to understand and contrast perceptions of palliative care among hematologic and solid tumor oncologists using surveys assessing referral practices and in-depth semistructured interviews exploring views of palliative care. We compared referral patterns using standard statistical methods. We analyzed qualitative interview data using constant comparative methods to explore reasons for observed differences.Results: Among 66 interviewees, 23 oncologists cared exclusively for patients with hematologic malignancies; 43 treated only patients with solid tumors. Seven (30%) of 23 hematologic oncologists reported never referring to palliative care; all solid tumor oncologists had previously referred. In qualitative analyses, most hematologic oncologists viewed palliative care as end-of-life care, whereas most solid tumor oncologists viewed palliative care as a subspecialty that could assist with complex patient cases. Solid tumor oncologists emphasized practical barriers to palliative care referral, such as appointment availability and reimbursement issues. Hematologic oncologists emphasized philosophic concerns about palliative care referrals, including different treatment goals, responsiveness to chemotherapy, and preference for controlling even palliative aspects of patient care. Conclusion: Most hematologic oncologists view palliative careas end-of-life care, whereas solid tumor oncologists more often view palliative care as a subspecialty for comanaging patients with complex cases. Efforts to integrate palliative care into hematologic malignancy practices will require solutions that address unique barriers to palliative care referral experienced by hematologic malignancy specialists.

show abstract

“…In a multicentre, cross-sectional study comprising 48 Italian hospitals, 1018 patients were analysed (Bandieri et al, 2010). It was shown that patients suffering from haematological malignancies have a high prevalence of pain.…”

Section: Prevalencementioning

confidence: 99%

“…In both solid and haematological tumours, fentanyl was the most frequent opioid used. The second most frequently used opioid was tramadol in haematological tumour patients and morphine in solid tumour patients (Bandieri et al, 2010).…”

Section: Prevalencementioning

confidence: 99%

Managing pain in oncology

Jain

2020

Journal of Prescribing Practice

View full text Add to dashboard Cite

Pain is one of the most common symptoms in cancer and almost all patients experience pain at various stages of the disease. Despite the high prevalence of these symptoms and various international guidelines that are in place for management, there is still a gap between the pain management approaches and achieving satisfactory pain relief. A holistic approach is required for effective management, which not only includes the pain-relieving medications but should also contain various complementary procedures to treat cancer pain and improve patients' quality of life.

show abstract

Is pain in patients with haematological malignancies under-recognised? The results from Italian ECAD-O survey

Cited by 17 publications

References 7 publications

Perceptions of Palliative Care Among Hematologic Malignancy Specialists: A Mixed-Methods Study

Perceptions of Palliative Care Among Hematologic Malignancy Specialists: A Mixed-Methods Study

Perceptions of palliative care among hematologic malignancy specialists: A mixed-methods study.

Managing pain in oncology

Contact Info

Product

Resources

About